<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566448</url>
  </required_header>
  <id_info>
    <org_study_id>WVU041011</org_study_id>
    <nct_id>NCT01566448</nct_id>
  </id_info>
  <brief_title>Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash</brief_title>
  <official_title>Treatment of Severe Mucositis Pain With Oral Ketamine Mouthwash</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aaron Cumpston, PharmD, BCOP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Virginia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oral mucositis (inflammation of the lining of the mouth) is a very common adverse effect when&#xD;
      chemotherapy and radiation therapy are used to treat cancer. Mucositis occurs in about 40% of&#xD;
      patients receiving standard dose chemotherapy, 80% of patients receiving radiation therapy of&#xD;
      the head and neck, and up to 100% of patients undergoing a bone marrow transplant. Because&#xD;
      the pain from mucositis can be so bad it can cause the inability to eat or drink, inability&#xD;
      to talk, gagging and drooling. Many times mucositis can affect cancer treatment because&#xD;
      patients may have to be given a lower dose of a drug or stop treatment completely. There are&#xD;
      not many treatments today that can help relieve the severe pain caused from mucositis. This&#xD;
      research study will help researchers determine if using an oral mouthwash called Ketamine&#xD;
      will help lessen mucositis pain.&#xD;
&#xD;
      Ketamine is approved by the Food and Drug Administration (FDA) for use with general&#xD;
      anesthesia, sedation and for severe pain. WVU Hospital is now using Ketamine mouthwash as a&#xD;
      standard treatment option for mucositis pain.&#xD;
&#xD;
      During this study patients will be assessed to determine the level of pain caused by their&#xD;
      mucositis. This will occur before the first dose, one hour after the first dose, and then&#xD;
      daily until they are no longer on the study. Patients will use the mouthwash by swishing and&#xD;
      spitting (20mg/5ml) four times each day, and also every four hours as needed. Patients will&#xD;
      use the mouthwash on this study until their mucositis gets better or until the mucositis gets&#xD;
      worse (or if the pain does not get better after three days of treatment).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mucositis&#xD;
&#xD;
      Mucositis is an adverse effect as a result of chemotherapy and radiation treatments and has&#xD;
      significant quality of life and clinical consequences. Mucositis is a result of direct&#xD;
      cytotoxic damage as well as a cytokine-mediated inflammatory response and can affect the&#xD;
      epithelial mucosal surfaces along the entire gastrointestinal tract. Mucositis manifesting in&#xD;
      the oral cavity can be especially distressing to patients and may involve erythema, cracking,&#xD;
      inflammation, bleeding and ulceration and typically begins 5-10 days after starting&#xD;
      chemotherapy. Mucositis occurs in about 40% of patients receiving standard dose chemotherapy,&#xD;
      80% of patients receiving radiation therapy to the head and neck, and up to 100% of patients&#xD;
      undergoing a bone marrow transplant.(1)&#xD;
&#xD;
      Pain from oral mucositis has been reported as the single most debilitating side effect by&#xD;
      patients receiving bone marrow transplants. Mucositis is also the most common condition&#xD;
      requiring analgesics during cancer therapy. Complications of pain from mucositis include&#xD;
      inability to tolerate food or fluid intake, difficulty or inability to talk, excess mucus,&#xD;
      gagging, sleep disturbances, and drooling. Mucositis may also require hospital admission or&#xD;
      extended admission for total parenteral nutrition, intravenous analgesia, and/or intravenous&#xD;
      antibiotics. Seventy percent of patients with a grade 3 or 4 mucositis will require a feeding&#xD;
      tube. Mucositis also has the potential to impact the effectiveness of cancer treatment as it&#xD;
      is a dose-limiting toxicity and results in cessation or reduction of treatment in 35% of&#xD;
      patients (2,3,4)&#xD;
&#xD;
      Current standard of care focuses on palliation and includes systemic opiate analgesics for&#xD;
      moderate to severe mucositis pain, topical anesthetics and mucosal coating agents such as&#xD;
      lidocaine, benzocaine, dyclonine, diphenhydramine, doxepin, and benzydamine for moderate&#xD;
      pain, and bland rinses for mild pain. Data supporting these management options are limited.&#xD;
      Other agents that have been investigated with variable responses are oral capsaicin, oral&#xD;
      sulfasalazine, and growth factor mouthwashes. (5)&#xD;
&#xD;
      Ketamine&#xD;
&#xD;
      Ketamine is a sedative hypnotic with anesthetic and analgesic properties. Ketamine works by&#xD;
      selectively depressing the thalamoneocortical system, non-competitively blocking&#xD;
      N-methyl-D-aspartate (NMDA) receptors, and having intrinsic sympathomimetic activity.&#xD;
      Ketamine also appears to selectively interrupt association pathways in the brain producing&#xD;
      somatesthetic sensory blockade. Ketamine is FDA-approved for induction and maintenance of&#xD;
      general anesthesia but has also been used for procedural sedation, refractory severe pain,&#xD;
      and acute respiratory failure in children. (6)&#xD;
&#xD;
      Topical administration of ketamine was shown to cause a reduction in allodynia in a&#xD;
      double-blind placebo controlled study and peripheral administration of ketamine has&#xD;
      antinociceptive efficacy similar to that of systemic administration which is likely mediated&#xD;
      by NMDA antagonism (7). Ketamine may also potentiate the effects of other systemic opioid&#xD;
      analgesics and may reverse opiate tolerance to some degree. Also, given that topical&#xD;
      administration of opiates has a local effect, topical ketamine may produce a local tolerance&#xD;
      reversal. Ketamine also has modest anti-inflammatory properties which could provide&#xD;
      beneficial effects in mucositis pain relief. (8)&#xD;
&#xD;
      Ketamine oral rinse use was described in a case report of a 32 year old female with&#xD;
      radiation-induced mucositis pain refractory to Clark's solution, transdermal fentanyl, and&#xD;
      intravenous hydromorphone. Ketamine oral rinse was given as 20mg of drug in a 5ml artificial&#xD;
      saliva solution every 3 hours as needed with continued PCA use. She experienced decreased&#xD;
      pain at rest and with eating and was able to decrease the dose of her opiate analgesics. Her&#xD;
      overall pain was reported as decreased from 9/10 to 3/10 with oral ketamine use. No adverse&#xD;
      effects were reported other than one episode of swallowing the solution which resulted in&#xD;
      transient sedative and psychomotor effects. (8)&#xD;
&#xD;
      A retrospective chart review of ketamine mouthwash use in 8 patients over a period of 4 years&#xD;
      was conducted to determine safety and efficacy. Patients in this review received ketamine&#xD;
      20mg/5ml mouthwashes every 4 hours as needed. Seven of the 8 patients were post-hematopoietic&#xD;
      stem cell transplant (post-HSCT) patients. Five patients had a documented improvement in&#xD;
      mucositis pain and 4 patients experienced an adverse event. Adverse events consisted of mild&#xD;
      confusion, nausea, vertigo, and hallucinations; however 2 of the 4 patients had reports of&#xD;
      these symptoms prior to beginning ketamine mouthwashes but were still included in the&#xD;
      analysis. Patients received an average of 17 doses over an average of 6 days. Reporting of&#xD;
      pain scores were variable and difficult to quantify but the authors concluded that ketamine&#xD;
      may provide a viable treatment option for mucositis pain. (9)&#xD;
&#xD;
      Rationale for study&#xD;
&#xD;
      Evidence for the use of an oral ketamine rinse suggests that it could provide a distinct&#xD;
      benefit for patients suffering from pain and other clinical consequences of mucositis as a&#xD;
      result of cancer treatments. No treatment is currently available that provides a profound&#xD;
      relief from this pain and available evidence suggests that ketamine could be a useful tool in&#xD;
      the arsenal of agents available to patients. Ketamine mouthwash was approved by the WVUH&#xD;
      Pharmacy Nutrition and Therapeutics (PNT) Committee as a treatment option for mucositis pain.&#xD;
      It is commercially available and currently used at our hospital. No prospective data exists&#xD;
      objectively evaluating the potential benefits and possible adverse effects of ketamine oral&#xD;
      rinse. We postulate that using ketamine as an oral mouthwash will provide pain relief for&#xD;
      patients with significant distress due to pain from oral mucositis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Pain Scores</measure>
    <time_frame>1 hour after baseline</time_frame>
    <description>Change in pain score as reported at baseline and after the use of ketamine mouthwash on a numeric scale from 0 to 10, with 0 representing no pain and 10 representing the worst pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time From Dose Administration to Change in Pain Intensity as Reported by Subject.</measure>
    <time_frame>1 day after start of ketamine mouthwashes</time_frame>
    <description>Patients will be questioned about time until maximal pain relief and given options of: no effect, 1-15 minutes, 15-30 minutes, 30-45 minutes, 45-60 minutes and greater than 1 hour.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Effect of Pain Reduction</measure>
    <time_frame>Day 1 after start of ketamine mouthwashes</time_frame>
    <description>Patients will be question about the duration of pain relief and given the option of no effect, less than one hour, 1-2 hours, 2-3 hours, 3-4 hours, greater than 4 hours or N/A.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Use of Narcotic Analgesics</measure>
    <time_frame>Days 1 after start of ketamine mouthwashes</time_frame>
    <description>Change in IV morphine equivalents of opioid requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Topical Lidocaine Usage</measure>
    <time_frame>Days 1 after start of ketamine mouthwashes</time_frame>
    <description>Change of topical lidocaine uses in 24 hour period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Quality</measure>
    <time_frame>Day 1 after start of ketamine mouthwashes</time_frame>
    <description>Sleep quality, as reported by the subject on a numeric scale (1-10) will be used as a surrogate marker of quality of life with 0 indicating no sleep and 10 indicating the best sleep you have had.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Mucositis</condition>
  <arm_group>
    <arm_group_label>Ketamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>20mg/5ml swish and spit four times daily</description>
    <arm_group_label>Ketamine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient has oral mucositis pain that is grade 3 or 4 according to the World Health&#xD;
             Organization (WHO) Oral Mucositis Scale&#xD;
&#xD;
          -  Patient has received at least one prior chemotherapy or radiation treatment&#xD;
&#xD;
          -  Patient is at least 18 years old&#xD;
&#xD;
          -  Patient or their legally authorized representative understands and voluntarily signs&#xD;
             the written informed consent prior to any study-specific procedures. A copy of the&#xD;
             signed informed consent form will be retained by the treating institution.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron Cumpston, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>West Virginia University Hospitals Mary Babb Randolph Cancer Center</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://wvucancer.org</url>
    <description>West Virginia University Mary Babb Randolph Cancer Center</description>
  </link>
  <reference>
    <citation>Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006 Sep;2(3):251-8.</citation>
    <PMID>18360600</PMID>
  </reference>
  <reference>
    <citation>Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ. Patient reports of complications of bone marrow transplantation. Support Care Cancer. 2000 Jan;8(1):33-9.</citation>
    <PMID>10650895</PMID>
  </reference>
  <reference>
    <citation>Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, Bekele BN, Raber-Durlacher J, Donnelly JP, Rubenstein EB; Mucositis Study Section of the Multinational Association for Supportive Care in Cancer; International Society for Oral Oncology. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004 May 1;100(9 Suppl):1995-2025. Review.</citation>
    <PMID>15108222</PMID>
  </reference>
  <reference>
    <citation>Borbasi S, Cameron K, Quested B, Olver I, To B, Evans D. More than a sore mouth: patients' experience of oral mucositis. Oncol Nurs Forum. 2002 Aug;29(7):1051-7.</citation>
    <PMID>12183754</PMID>
  </reference>
  <reference>
    <citation>Bensinger W, Schubert M, Ang KK, Brizel D, Brown E, Eilers JG, Elting L, Mittal BB, Schattner MA, Spielberger R, Treister NS, Trotti AM 3rd. NCCN Task Force Report. prevention and management of mucositis in cancer care. J Natl Compr Canc Netw. 2008 Jan;6 Suppl 1:S1-21; quiz S22-4. Review.</citation>
    <PMID>18289497</PMID>
  </reference>
  <reference>
    <citation>Ketamine. Clinical Pharmacology Online. Elsevier/Gold Standard, Inc. 15 Nov 2011.</citation>
  </reference>
  <reference>
    <citation>Finch PM, Knudsen L, Drummond PD. Reduction of allodynia in patients with complex regional pain syndrome: A double-blind placebo-controlled trial of topical ketamine. Pain. 2009 Nov;146(1-2):18-25. doi: 10.1016/j.pain.2009.05.017. Epub 2009 Aug 22.</citation>
    <PMID>19703730</PMID>
  </reference>
  <reference>
    <citation>Slatkin NE, Rhiner M. Topical ketamine in the treatment of mucositis pain. Pain Med. 2003 Sep;4(3):298-303.</citation>
    <PMID>12974832</PMID>
  </reference>
  <reference>
    <citation>Ryan AJ, Lin F, Atayee RS. Ketamine mouthwash for mucositis pain. J Palliat Med. 2009 Nov;12(11):989-91. doi: 10.1089/jpm.2009.0198.</citation>
    <PMID>19708855</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 27, 2012</study_first_submitted>
  <study_first_submitted_qc>March 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <results_first_submitted>May 29, 2018</results_first_submitted>
  <results_first_submitted_qc>December 15, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2021</results_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>West Virginia University</investigator_affiliation>
    <investigator_full_name>Aaron Cumpston, PharmD, BCOP</investigator_full_name>
    <investigator_title>Pharmacy Clinical Specialist (Principal Investigator)</investigator_title>
  </responsible_party>
  <keyword>Ketamine</keyword>
  <keyword>Mucositis</keyword>
  <keyword>Oral ketamine rinse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ketamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ketamine</title>
          <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ketamine</title>
          <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Pain Scores</title>
        <description>Change in pain score as reported at baseline and after the use of ketamine mouthwash on a numeric scale from 0 to 10, with 0 representing no pain and 10 representing the worst pain.</description>
        <time_frame>1 hour after baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Pain Scores</title>
          <description>Change in pain score as reported at baseline and after the use of ketamine mouthwash on a numeric scale from 0 to 10, with 0 representing no pain and 10 representing the worst pain.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Dose Administration to Change in Pain Intensity as Reported by Subject.</title>
        <description>Patients will be questioned about time until maximal pain relief and given options of: no effect, 1-15 minutes, 15-30 minutes, 30-45 minutes, 45-60 minutes and greater than 1 hour.</description>
        <time_frame>1 day after start of ketamine mouthwashes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Dose Administration to Change in Pain Intensity as Reported by Subject.</title>
          <description>Patients will be questioned about time until maximal pain relief and given options of: no effect, 1-15 minutes, 15-30 minutes, 30-45 minutes, 45-60 minutes and greater than 1 hour.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No effect</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>0-15 minutes</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Effect of Pain Reduction</title>
        <description>Patients will be question about the duration of pain relief and given the option of no effect, less than one hour, 1-2 hours, 2-3 hours, 3-4 hours, greater than 4 hours or N/A.</description>
        <time_frame>Day 1 after start of ketamine mouthwashes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Effect of Pain Reduction</title>
          <description>Patients will be question about the duration of pain relief and given the option of no effect, less than one hour, 1-2 hours, 2-3 hours, 3-4 hours, greater than 4 hours or N/A.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;1 hour</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-2 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-3 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3-4 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;4 hours</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No effect</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Use of Narcotic Analgesics</title>
        <description>Change in IV morphine equivalents of opioid requirements</description>
        <time_frame>Days 1 after start of ketamine mouthwashes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Use of Narcotic Analgesics</title>
          <description>Change in IV morphine equivalents of opioid requirements</description>
          <units>IV morphine equivalents</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12" lower_limit="0" upper_limit="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Topical Lidocaine Usage</title>
        <description>Change of topical lidocaine uses in 24 hour period</description>
        <time_frame>Days 1 after start of ketamine mouthwashes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Topical Lidocaine Usage</title>
          <description>Change of topical lidocaine uses in 24 hour period</description>
          <units>lidocaine doses per day</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Sleep Quality</title>
        <description>Sleep quality, as reported by the subject on a numeric scale (1-10) will be used as a surrogate marker of quality of life with 0 indicating no sleep and 10 indicating the best sleep you have had.</description>
        <time_frame>Day 1 after start of ketamine mouthwashes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ketamine</title>
            <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Sleep Quality</title>
          <description>Sleep quality, as reported by the subject on a numeric scale (1-10) will be used as a surrogate marker of quality of life with 0 indicating no sleep and 10 indicating the best sleep you have had.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ketamine</title>
          <description>Ketamine oral mouthwash 20mg/5ml swish and spit four times daily&#xD;
Ketamine: 20mg/5ml swish and spit four times daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Aaron Cumpston</name_or_title>
      <organization>West Virginia University Hospitals</organization>
      <phone>304-598-4000 ext 73350</phone>
      <email>cumpstona@wvumedicine.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

